Cyproheptadine-Prazosin Combination for AUD
April 24, 2024
A recent double-blind, parallel group, placebo-controlled Phase 2 c...
Read More
FDA Approves First Test to Help Identify Risk of Opioid Use Disorder
December 23, 2023
The U.S. Food and Drug Administration approved the first genetic te...
Read More
Risk of Progression From Mild or Moderate to Severe Alcohol Use Disorder
October 19, 2023
Predicting the development of severe alcohol use disorder is diffic...
Read More
Substance-Induced Psychosis Tied to Schizophrenia Risk
October 17, 2023
individuals without a history of psychosis were assessed for the li...
Read More
AAFP Updates Alcohol Use Practice Manual
October 8, 2023
The AAFP has recently published an updated practice manual on addre...
Read More
Genetic Link Between Eating Disorders and Alcohol Use
October 2, 2023
Previous research has shown a connection between eating disorders a...
Read More
Integrating Opioid Use Disorder Treatment Into Primary Care Settings
September 7, 2023
Opioid use disorder (OUD) is undertreated even though there are eff...
Read More
Injection Drug Use Frequency Before and After Take-Home Naloxone Training
August 17, 2023
Naloxone, a medication designed to quickly reverse opioid overdose,...
Read More
FDA Issues Draft Guidance on Psychedelic Drug Trials
July 22, 2023
While there is still much to learn about the potential therapeutic ...
Read More
Psychedelics and PTSD
July 19, 2023
At this moment, of the two drugs, MDMA-assisted psychotherapy has s...
Read More
Stimulant Treatment in Youth Not Associated With Substance Use Later in Life
July 16, 2023
Childhood attention-deficit/hyperactivity disorder (ADHD) is linked...
Read More
Patterns in Nicotine Dependence Prevalence
July 6, 2023
Smoking remains a leading global cause of preventable death and dis...
Read More